OSI Pharmaceuticals
USINFO | 2013-08-06 09:53
Type Subsidiary
Industry Biopharmaceuticals &Biotherapeutics[1]
Founded 1983
Headquarters Melville, New York
Key people Colin Goddard, CEO
Michael G. Atieh, CFO
Robert A. Ingram, Chairman[1]
Products Medical Laboratories & Research
Revenue $375.7 MillionUSD(2006)[2]
Net income $-582.2 Million USD(2006)[2]
Employees 554 (2007-02)[3]
Parent Astellas Pharma (2010-present)
Website www.osip.com

OSI Pharmaceuticals, Inc. is an American pharmaceutical company based in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. OSI specializes in the discovery and development of molecular targeted therapies. Though oncology is the top priority for OSI, research and development targeting type 2 diabetes and obesity is conducted through their U.K. subsidiaryProsidion Limited.[4][1] OSI has also made a foray into the ophthalmology market through a marketing agreement with Pfizer over Macugen (Pegaptanib) for Age-related macular degeneration; however, acquisition of the firm Eyetech, meant to provide control over this product and diversify the company, has been unsuccessful, ending in divestiture.[5][6]
In mid-2007, OSI's revenues were based primarily on proceeds from Tarceva sales (which are shared with Genentech and Hoffmann–La Roche) and royalty payments related to dipeptidyl-peptidase IVinhibitor intellectual property.[5]
On June 9, 2010, OSI was acquired by Japan-based, TSE-listed Astellas Pharma for $4.0 billion.

See also: Erlotinib
Tarceva (Erlotinib) was OSI's flagship and, as of 2007, only marketed product.[5][7] Tarceva is a small molecule inhibitor of the epidermal growth factor receptor (EGFR) and is the only EGFR inhibitor to have demonstrated the ability to improve overall survival in advanced non-small cell lung cancer and advanced pancreatic cancer.[4] Tarceva was discovered by Pfizer as CP-358774 (Moyer et al. Cancer Research, 1997, 57:4838), renamed OSI-774 when Pfizer was required to divest the compound in order to complete the buyout of Warner lambert/Parke-Davis and subsequently developed by OSI in conjunction with Genentech.
©2012-2014 Bywoon | Bywoon